Arch Oncology Names Dennison to Board of Directors
13 August 2019 - - US-based clinical-stage immuno-oncology company Arch Oncology, Inc has appointed Drew Dennison to the company's board of directors, the company said.

Drew Dennison is Managing director at Lightchain Capital, LLC, the family office for Scottrade Founder and former chief executive officer Rodger Riney. At Lightchain, Dennison is responsible for venture capital investments in the life science and technology sectors.

He also assists the Riney Foundations with their philanthropic endeavors. Previously, Dennison served as the chief operating officer and chief financial officer at Scottrade Financial Services, Inc.

He led the company's operations, technology, operations, finance, and strategic planning functions and worked at the company for over a decade.

Dennison led the sale of Scottrade to TD Ameritrade, then co-led the integration project, successfully combining the two companies.

In addition, Dennison serves as chairman of the board of CareVet Holdings and as a board member of FinTech Studios.

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer.

The company's next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.

Arch Oncology's lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the company is advancing a number of pipeline programs, including anti-signal regulatory protein antibodies.

Arch Oncology's leadership team has successfully developed new drugs for patients before and is backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, 3x5 RiverVest Partners II-B, and Lightchain.